每(mei)經(jing)AI快訊，有投資(zi)者在(zai)投資(zi)者互動平臺提問：公(gong)司在(zai)合成(cheng)生物學領(ling)域有哪(na)些成(cheng)就(jiu)和優(you)勢(shi)，對該領(ling)域未來有哪(na)些布局和看法

金城醫(yi)藥（300233.SZ）5月9日在投資者互動平臺(tai)(tai)表示，公(gong)(gong)(gong)司(si)(si)擁(yong)有(you)(you)生(sheng)物合成(cheng)(cheng)的研(yan)發及產(chan)業(ye)(ye)化平臺(tai)(tai)，具備從研(yan)發到(dao)中試再(zai)到(dao)產(chan)業(ye)(ye)化落地的產(chan)業(ye)(ye)鏈平臺(tai)(tai)優勢。公(gong)(gong)(gong)司(si)(si)擁(yong)有(you)(you)谷胱甘肽、腺苷蛋氨酸(suan)等(deng)支撐性(xing)產(chan)品(pin)，并成(cheng)(cheng)功運(yun)用酶催化技術提升4-AA、煙堿等(deng)產(chan)品(pin)質量和(he)效(xiao)率，啟動了國內第一(yi)家蝦青素產(chan)品(pin)的轉基因(yin)安全評(ping)價工(gong)作(zuo)。目前(qian)公(gong)(gong)(gong)司(si)(si)有(you)(you)多個合成(cheng)(cheng)生(sheng)物學(xue)產(chan)品(pin)在研(yan)，公(gong)(gong)(gong)司(si)(si)將(jiang)持續(xu)加(jia)大研(yan)發投入，強(qiang)化公(gong)(gong)(gong)司(si)(si)現有(you)(you)資源配置，形成(cheng)(cheng)更(geng)具競爭力的產(chan)業(ye)(ye)鏈及平臺(tai)(tai)優勢，推動公(gong)(gong)(gong)司(si)(si)向更(geng)高質量發展。

(記者 畢陸名)

免責聲(sheng)明(ming)：本文內容(rong)與數據僅供(gong)參考(kao)，不(bu)構(gou)成(cheng)投資(zi)建議，使用前核實(shi)。據此操(cao)作，風險自擔。